

1
2 **CLAIMS**
3

4 1. A method of treating rhinosinusitis or alleviating the symptoms of rhinosinusitis,
5 comprising
6 administering an agent that permits the release of proteins from the endoplasmic
7 reticulum.
8

9 2. The method of claim 1, wherein the agent is delivered intranasally.
10

11 3. The method of claim 1, further comprising the step of:
12 providing an individual suffering from rhinosinusitis.
13

14 4. The method of claim 3, wherein the providing step comprises providing an individual
15 suffering from chronic rhinosinusitis.
16

17 5. The method of claim 3, wherein the individual carries a mutation in at least one copy
18 of a gene encoding a cystic fibrosis transmembrane conductance regulator.
19

20 6. The method of claim 3, wherein the gene is the *CFTR* gene.
21

22 7. The method of claim 3, wherein the individual carries a mutation in one copy of the
23 gene.
24

25 8. The method of claim 3, wherein the individual carries a mutation in both copies of
26 the gene.
27

28 9. The method of claim 7 or claim 8, wherein the mutation is a $\Delta F508$ mutation.
29

30 10. The method of claim 9, wherein the individual carries an M470V variant of the
31 *CFTR* gene.
32

33 11. A method of treating hemochromatosis or alleviating the symptoms of
34 hemochromatosis, comprising

1 administering an agent that permits the release of proteins from the endoplasmic
2 reticulum.

3
4 12. The method of claim 11, further comprising the step of:
5 providing an individual suffering from hemochromatosis.

6
7 13. The method of claim 11, wherein the providing step comprises providing an
8 individual having a mutation in at least one copy of a gene encoding an HFE protein.

9
10 14. The method of claim 12, wherein the individual carries a mutation in one copy of
11 the gene.

12
13 15. The method of claim 12, wherein the individual carries a mutation in both copies of
14 the gene.

15
16 16. A method of treating Gitelman's syndrome or alleviating the symptoms of
17 Gitelman's syndrome, comprising
18 administering an agent that permits the release of proteins from the endoplasmic
19 reticulum.

20
21 17. The method of claim 16, further comprising the step of:
22 providing an individual suffering from Gitelman's syndrome.

23
24 18. The method of claim 17, wherein the individual carries a mutation in at least one
25 copy of a gene encoding a thiazide sensitive Na-Cl cotransporter.

26
27 19. The method of claim 18, wherein the gene is the *NCC* gene.

28
29 20. The method of claim 19, wherein the mutation is a G738R mutation.

30
31 21. The method of claim 18, wherein the individual carries a mutation in one copy of
32 the gene.

- 1 22. The method of claim 18, wherein the individual carries a mutation in both copies of
2 the gene.
3
- 4 23. A method of treating cystinuria or alleviating the symptoms of cystinuria,
5 comprising administering an agent that permits the release of proteins from the
6 endoplasmic reticulum.
7
- 8 24. The method of claim 23, further comprising the step of:
9 providing an individual suffering from cystinuria.
10
- 11 25. The method of claim 24, wherein the providing step comprises providing an
12 individual suffering from type I cystinuria.
13
- 14 26. The method of claim 24, wherein the individual carries a mutation in at least one
15 copy of a gene encoding a subunit of an rBAT protein.
16
- 17 27. The method of claim 26, wherein the individual carries a mutation in one copy of
18 the gene.
19
- 20 28. The method of claim 26, wherein the individual carries a mutation in both copies of
21 the gene.
22
- 23 29. The method of any of claims 3, 12, 17, or 24, wherein the agent is a calcium pump
24 inhibitor.
25
- 26 30. The method of any of claims 3, 12, 17, or 24, wherein the agent decreases or
27 inhibits the activity of UDP glucose:glycoprotein glycosyl transferase.
28
- 29 31. The method of any of claims 3, 12, 17, or 24, wherein the agent decreases or
30 inhibits activity of the endoplasmic reticulum Ca^{++} ATPase.
31
- 32 32. The method of any of claims 3, 12, 17, or 24, wherein the agent lowers the
33 concentration of Ca^{++} in the endoplasmic reticulum.
34